Author:
Wang Zhonghao,Kong Qiong,Su Peng,Duan Miao,Xue Min,Li Xin,Tang Jianing,Gao Zhitao,Wang Beibei,Li Zhongbo,Liu Yun,Yang Xiao,Cao Ruilin,Song Tingting,Wang Ke,Cai Yuqing,Wu Danfeng,Li Jinglei,Wu Gaosong,Guled Asha M.,Zhu Jian,Yan Cheng,Zhuang Ting
Abstract
AbstractBreast cancer is the most common malignancy for women worldwide, while Triple Negative Breast Cancer (TNBC) accounts for 20% in all patients. Compared with estrogen receptor positive breast cancer, which could be effectively controlled via endocrine therapy, TNBC is more aggressive and worse in prognosis. It is therefore urgent and necessary to develop a novel therapeutic strategy for TNBC treatment. Recent studies identified Hippo signaling is highly activated in TNBC, which could be a driving pathway for TNBC progression. In our study, we determine RNF187 as a negative regulator for Hippo signaling activation. RNF187 depletion significantly decreases cell migration and invasion capacity in TNBC. These effects could be rescued by further YAP depletion. Depletion of RNF187 increases the YAP protein level and Hippo signaling target genes, such as CTGF and CYR61 in TNBC. Immuno-precipitation assay shows that RNF187 associates with YAP, promoting its degradation possibly via inducing YAP K48-dependent poly-ubiquitination. Interestingly, Our clinical data reveals that RNF187 reversely correlates with YAP protein level and Hippo target genes. RNF187 tends to correlate with good prognosis in TNBC patients. Our study provides evidence to establish a proteolytic mechanism in regulation Hippo signaling activation in TNBC.
Funder
the Joint Fund of the National Natural Science Foundation of China
Shandong Provincial National Natural Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献